High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy
| العنوان: | High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy |
|---|---|
| المؤلفون: | Charlotte E. Ariyan, Jessica M. Sta.Cruz, Michael A. Postow, Richard Ferraro, Jessica Flynn, Katherine S. Panageas, Edmund K. Bartlett, Daniel G. Coit |
| المصدر: | Cancer |
| بيانات النشر: | Wiley, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, Male, Cancer Research, medicine.medical_specialty, Neutrophils, Programmed Cell Death 1 Receptor, Kaplan-Meier Estimate, Single Center, Gastroenterology, Disease-Free Survival, Article, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Humans, In patient, Lymphocyte Count, Lymphocytes, 030212 general & internal medicine, Neutrophil to lymphocyte ratio, Melanoma, Aged, Neoplasm Staging, Aged, 80 and over, business.industry, fungi, Hazard ratio, Cancer, Middle Aged, Prognosis, medicine.disease, Oncology, 030220 oncology & carcinogenesis, Cohort, Biomarker (medicine), Female, business |
| الوصف: | BACKGROUND An elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poor survival in patients with cancer, including those who receive immunotherapies. The authors sought to investigate NLR as a biomarker of treatment outcomes in patients with melanoma who were treated with PD-1 inhibition. METHODS Patients undergoing initial treatment with PD-1 inhibitor monotherapy for stage IV melanoma at a single center from 2012 to 2015 were included. Clinical characteristics and the NLR at baseline and before subsequent treatment cycles were collected. The time to treatment failure (TTF) and overall survival (OS) were evaluated using Kaplan-Meier and landmark analyses. RESULTS Among 224 study patients, 63 (28%) had a baseline NLR ≥5. The baseline NLR was significantly associated with Eastern Cooperative Oncology Group performance status and the number of involved metastatic sites. With a median follow-up of 39 months in survivors, a baseline NLR ≥5 was independently associated with shorter OS (hazard ratio, 2.0; 95% CI, 1.3-2.9) and TTF (hazard ratio, 1.7; 95% CI, 1.2-2.4). An NLR increase ≥30% during the first 2 cycles of treatment was associated with worse OS (median, 47 vs 13.5 months; P |
| تدمد: | 1097-0142 0008-543X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::727cec8509d491c46a2a16f9eaf14db9Test https://doi.org/10.1002/cncr.32506Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....727cec8509d491c46a2a16f9eaf14db9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10970142 0008543X |
|---|